The most compelling proof of TACE activity's involvement in MASH‐HCC, mediated by AATF, lies in the observation that Marimastat, a TACE inhibitor, reduces JNK, ERK1/2, and AKT activation in AATF control cells. The gene discussed is ADAM17; the disease is hepatocellular carcinoma.